Citations

Clear

590 citation(s) found for "Ho, Ben".

“Nothing burns like the cold”: Cardiovascular disease in frigid zones
Lerman, Ben , Lerman, Lilach O.

Mayo Clinic

Frigid Zone Medicine | September 29, 2022 | Volume: 2 | Issue: 3 | Pages: 129-131

10.2478/fzm-2022-0017 Get It

Shorter versus longer corticosteroid duration and recurrent immune checkpoint inhibitor-associated AKI
García-Carro, Clara , Prosek, Jason, Garcia, Pablo, Abudayyeh, Ala , Lumlertgul, Nuttha , Malik, Abhinav , Loew, Sebastian, Beckerman, Pazit , Renaghan, Amanda DeMauro , Carlos, Christopher A., Rashidi, Arash , Mithani, Zain, Deshpande, Priya , Rangarajan, Sunil , Seigneux, Sophie de , Campedel, Luca , Shin, Daniel Sanghoon , Coppock, Gaia, Ortiz-Melo, David I. , Aggarwal, Vikram , Benesova, Karolina, Wanchoo, Rimda, Murakami, Naoka , Cortazar, Frank B. , Reynolds, Kerry L. , Sise, Meghan E. , Soler, María José , Leaf, David E. , Bermejo, Sheila , Salem, Joe‐Elie , Gupta, Shruti , Kitchlu, Abhijat , Reynolds, Kerry L , Soler, Maria Jose , Leaf, David E , Murakami, Naoka , Salem, Joe-Elie , Koessler, Thibaud , Gupta, Shruti , Glezerman, Ilya G , Herrmann, Sandra M. , Malik, A Bilal, Shah, Chintan V , Kitchlu, Abhijat , Sprangers, Ben

Mayo Clinic

Journal for ImmunoTherapy of Cancer | September 22, 2022 | Volume: 10 | Issue: 9 | Pages: e005646

10.1136/jitc-2022-005646 | PMID 36137651 Get It

Background Corticosteroids are the mainstay of treatment for immune checkpoint inhibitor-associated acute kidney injury (ICPi-AKI), but the optimal duration of therapy has not been established. Prolonged use of corticosteroids can cause numerous adverse effects and may decrease progression-free survival among patients treated with ICPis. We sought to determine whether a shorter duration of corticosteroids was equally efficacious and safe as compared with a longer duration. Methods We used data from an international multicenter cohort study of patients diagnosed with ICPi-AKI from 29 centers across nine countries. We examined whether a shorter duration of corticosteroids (28 days or less) was associated with a higher rate of recurrent ICPi-AKI or death within 30 days following completion of corticosteroid treatment as compared with a longer duration (29–84 days). Results Of 165 patients treated with corticosteroids, 56 (34%) received a shorter duration of treatment and 109 (66%) received a longer duration. Patients in the shorter versus longer duration groups were similar with respect to baseline and ICPi-AKI characteristics. Five of 56 patients (8.9%) in the shorter duration group and 12 of 109 (11%) in the longer duration group developed recurrent ICPi-AKI or died (p=0.90). Nadir serum creatinine in the first 14, 28, and 90 days following completion of corticosteroid treatment was similar between groups (p=0.40, p=0.56, and p=0.89, respectively). Conclusion A shorter duration of corticosteroids (28 days or less) may be safe for patients with ICPi-AKI. However, the findings may be susceptible to unmeasured confounding and further research from randomized clinical trials is needed.
Integrative Medicine for Pain Management in Oncology: Society for Integrative Oncology–ASCO Guideline
Mao, Jun J. , Ismaila, Nofisat , Bao, Ting , Barton, Debra L. , Ben‐Arye, Eran , Garland, Eric L. , Greenlee, Heather , LeBlanc, Thomas W. , Lee, Richard T. , López, Ana María , Loprinzi, Charles L. , MacLeod, Jodi , Master, Viraj A. , Ramchandran, Kavitha , Walker, Eleanor , Witt, Claudia M. , Barton, Debra , Leblanc, Thomas , Loprinzi, Charles , Lyman, Gary H , MacLeod, Jodi , Wagner, Lynne , Bruner, Deborah , Witt, Claudia M , Bruera, Eduardo , Mao, Jun J , Ramchandran, Kavitha J , Wagner, Lynne I. , Bruner, Deborah Watkins

Mayo Clinic

Journal of Clinical Oncology | September 19, 2022 | Volume: 40 | Issue: 34 | Pages: 3998-4024

10.1200/jco.22.01357 | PMID 36122322 Get It

PURPOSE The aim of this joint guideline is to provide evidence-based recommendations to practicing physicians and other health care providers on integrative approaches to managing pain in patients with cancer. METHODS The Society for Integrative Oncology and ASCO convened an expert panel of integrative oncology, medical oncology, radiation oncology, surgical oncology, palliative oncology, social sciences, mind-body medicine, nursing, and patient advocacy representatives. The literature search included systematic reviews, meta-analyses, and randomized controlled trials published from 1990 through 2021. Outcomes of interest included pain intensity, symptom relief, and adverse events. Expert panel members used this evidence and informal consensus to develop evidence-based guideline recommendations. RESULTS The literature search identified 227 relevant studies to inform the evidence base for this guideline. RECOMMENDATIONS Among adult patients, acupuncture should be recommended for aromatase inhibitor–related joint pain. Acupuncture or reflexology or acupressure may be recommended for general cancer pain or musculoskeletal pain. Hypnosis may be recommended to patients who experience procedural pain. Massage may be recommended to patients experiencing pain during palliative or hospice care. These recommendations are based on an intermediate level of evidence, benefit outweighing risk, and with moderate strength of recommendation. The quality of evidence for other mind-body interventions or natural products for pain is either low or inconclusive. There is insufficient or inconclusive evidence to make recommendations for pediatric patients. More research is needed to better characterize the role of integrative medicine interventions in the care of patients with cancer. Additional information is available at https://integrativeonc.org/practice-guidelines/guidelines and www.asco.org/survivorship-guidelines .
Standards of Care for the Health of Transgender and Gender Diverse People, Version 8
Coleman, Eli , Bouman, Walter Pierre , Brown, George R. , Vries, A. de , Deutsch, Madeline B. , Ettner, Randi, Fraser, Lin, Goodman, Michael , Green, J., Hancock, Adrienne B. , Johnson, Thomas W. , Karasic, Dan H., Knudson, Gail, Leibowitz, Scott , Meyer‐Bahlburg, Heino F. L. , Monstrey, S., Motmans, Joz , Nahata, Leena , Reisner, Sari L. , Richards, Christina , Schechter, Loren S. , Tangpricha, Vin , Tishelman, Amy C. , Trotsenburg, M.A.A. van , Winter, Sam , Ducheny, Kelly , Adams, Noah S. , Adrián, T. M., Allen, Luke R. , Azul, David , Bagga, Harjit, Başar, Koray , Bathory, D. S., Belinky, Javier, Berg, Dianne , Berli, Jens U. , Bluebond‐Langner, Rachel , Bouman, Mark‐Bram , Bowers, Marci, Brassard, P., Byrne, Jack, Cargill, C. J., Carswell, Jeremi M. , Chang, Sand C. , Chelvakumar, Gayathri, Corneil, Trevor , Dalke, Katharine B. , Cuypere, Griet De , Vries, Elma De , Devor, Aaron , D’Marco, A., Edmiston, E. Kale , Edwards-Leeper, Laura, Ehrbar, Randall D., Ehrensaft, Diane , Eisfeld, Justus, Elaut, Els , Erickson‐Schroth, Laura, Feldman, Jamie , Garcia, Maurice M. , Gijs, Luk , Green, S. E., Hall, B. P., Hardy, Teresa L. D. , Jacobs, Laura A., Klink, Daniel, Kuper, Laura E. , Kvach, Elizabeth, Malouf, Matthew A., Massey, Ren, Mazur, Tom, McLachlan, Chris tine, Mosser, Scott W., Neira, Paula M. , Nygren, Ulrika , Oates, Jennifer , Pagkalos, Georgios, Patton, J., Rachlin, Katherine, Reed, T., Rider, G. Nic , Ristori, Jiska , Robbins-Cherry, Sally, Roberts, Stephanie , Sabir, K., Seal, Leighton , Sehoole, T. J. , Spencer, K., Amand, Colt St. , Strang, John F. , Taylor, G. B., Vala, L. N., Vencill, Jennifer A. , Wesp, Linda , Rider, G. Nic , Tangpricha, Vin , Roberts, Stephanie A , Radix, Asa E. , Nieder, Timo Ole , Capitán, Luis Pérez , Heijer, Martin den , Dhejne, Cecilia , Fisher, Alessandra D. , Irwig, Michael S. , Jacobs, L. A., Janssen, Aron C. , Johnson, Katherine , Kreukels, Baudewijntje P.C. , McLachlan, Christine , Morrison, Shane D. , Obedin‐Maliver, Juno , Phanuphak, Nittaya , Reed, T., Rodriguez-Wallberg, Kenny A , Rosenthal, Stephen M. , Safer, Joshua D. , Scheim, Ayden I. , Steensma, Thomas D. , Tilleman, Kelly , T’Sjoen, Guy , Mello, Norah M. van , Veale, Jaimie F. , Vincent, Ben , West, Michael A. , Arcelus, Jon

Mayo Clinic

International Journal of Transgender Health | September 6, 2022 | Volume: 23 | Issue: sup1 | Pages: S1-S259

10.1080/26895269.2022.2100644 | PMID 36238954 Get It

A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma
D’Souza, Anita , Shah, Nina , Rodriguez, Cesar, Voorhees, Peter M. , Bueno, Orlando F. , Pothacamury, Rajvineeth Kumar, Freise, Kevin J. , Yue, Susan, Ross, Jeremy A. , Polepally, Akshanth R. , Talati, Chetasi, Buelow, Ben , Vij, Ravi , Kumar, Shaji , Polepally, Akshanth R , Buelow, Ben , Vij, Ravi , Kumar, Shaji K , D'Souza, Anita , Voorhees, Peter , Weisel, Katja C , Talati, Chetasi , Lee, Shane , Jin, Ziyi

Mayo Clinic

Journal of Clinical Oncology | August 27, 2022 | Volume: 40 | Issue: 31 | Pages: 3576-3586

10.1200/jco.22.01504 | PMID 36029527 Get It

PURPOSE ABBV-383, a B-cell maturation antigen × CD3 T-cell engaging bispecific antibody, has demonstrated promising results in an ongoing first-in-human phase I study (ClinicalTrials.gov identifier: NCT03933735 ) in patients with relapsed/refractory multiple myeloma (RRMM). Herein, we report safety and efficacy outcomes of this phase I dose escalation/expansion study. METHODS Patients with RRMM (≥ three prior lines including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody) were eligible. ABBV-383 was administered intravenously over 1-2 hours once every 3 weeks, without any step dosing. A 3 + 3 design with backfilling for dose escalation was used (intrapatient escalation to highest safe dose permitted) followed by initiation of dose expansion. RESULTS As of January 8, 2022, 124 patients (dose escalation [0.025-120 mg], n = 73; dose expansion [60 mg], n = 51) have received ABBV-383; median age was 68 years (range, 35-92 years). The most common hematologic treatment-emergent adverse events (TEAEs) were neutropenia (all grades: 37%) and anemia (29%). The most common nonhematologic TEAEs were cytokine release syndrome (57%) and fatigue (30%). Seven deaths from TEAEs were reported with all considered unrelated to study drug by the investigator. For all efficacy-evaluable patients (n = 122; all doses), the objective response rate (ORR) was 57% and very good partial response (VGPR) or better (≥ VGPR) rate was 43%. In the 60 mg dose expansion cohort (n = 49), the ORR and ≥ VGPR rates were 59% and 39%, respectively; and in the ≥ 40 mg dose escalation plus dose expansion cohorts (n = 79) were 68% and 54%, respectively. CONCLUSION ABBV-383 in patients with RRMM was well tolerated with an ORR of 68% at doses ≥ 40 mg. This novel therapy's promising preliminary antitumor activity in heavily pretreated patients warrants further clinical evaluation.
Glutamate Neurotoxicity and Destruction of the Blood–Brain Barrier: Key Pathways for the Development of Neuropsychiatric Consequences of TBI and Their Potential Treatment Strategies
Gruenbaum, Benjamin F. , Frenkel, Amit , Boyko, Matthew , Frenkel, Amit , Boyko, Matthew , Gruenbaum, Benjamin Fredrick , Zlotnik, Alexander Anatolievich , Fleidervish, Ilya A.

Mayo Clinic

International Journal of Molecular Sciences | August 25, 2022 | Volume: 23 | Issue: 17 | Pages: 9628

10.3390/ijms23179628 | PMID 36077024 Get It

Traumatic brain injury (TBI) is associated with significant cognitive and psychiatric conditions. Neuropsychiatric symptoms can persist for years following brain injury, causing major disruptions in patients’ lives. In this review, we examine the role of glutamate as an aftereffect of TBI that contributes to the development of neuropsychiatric conditions. We hypothesize that TBI causes long-term blood–brain barrier (BBB) dysfunction lasting many years and even decades. We propose that dysfunction in the BBB is the central factor that modulates increased glutamate after TBI and ultimately leads to neurodegenerative processes and subsequent manifestation of neuropsychiatric conditions. Here, we have identified factors that determine the upper and lower levels of glutamate concentration in the brain after TBI. Furthermore, we consider treatments of disruptions to BBB integrity, including repairing the BBB and controlling excess glutamate, as potential therapeutic modalities for the treatment of acute and chronic neuropsychiatric conditions and symptoms. By specifically focusing on the BBB, we hypothesize that restoring BBB integrity will alleviate neurotoxicity and related neurological sequelae.
Analysis of somatic mutations in 131 human brains reveals aging-associated hypermutability
Bae, Taejeong , Fasching, Liana , Wang, Yifan , Shin, Joo Heon , Šuvakov, Milovan , Jang, Yeongjun , Norton, Scott , Dias, Caroline , Mariani, Jessica , Jourdon, Alexandre , Wu, Feinan , Panda, Arijit , Pattni, Reenal , Chahine, Yasmine, Yeh, Rebecca C., Roberts, Rosalinda C. , Hüttner, Anita , Straub, Richard E. , Walsh, Christopher A. , Network§, Brain Somatic Mosaicism, Urban, Alexander E. , Weinberger, Daniel R. , Vaccarino, Flora M. , Abyzov, Alexej , Šestan, Nenad , Moran, John V. , Gleeson, Joseph G. , Mathern, Gary W. , Courchesne, Eric, Chess, Andrew , Bizzotto, Sara , D’Gama, Alissa M. , Hill, Robert , Kim, Sonia , Miller, Michael , Borges-Monroy, Rebeca , Bohrson, Craig L. , Galor, Alon , Kwon, Min‐Seok , Luquette, Joe, Sherman, Maxwell A. , Rosenbluh, Chaggai , Cho, Sean, Thorpe, Jeremy , McConnell, Michael J. , Narurkar, Rujuta, Paquola, Apuã C.M. , Shin, Jooheon, Molitor, Cindy, Peters, Mette A. , Linker, Sara B. , Reed, Patrick , Wang, Meiyan , Zhou, Bo , Amero, Aitor Serres, Lobón, Irene , Moruno, Manuel Solis, Pérez, Raquel García, Povolotskaya, Inna , Soriano, Eduardo , Antaki, Danny , Averbuj, Dan, Ball, Laurel, Yang, Xiaoxu , Chung, Changuk , Emery, Sarah B., Flasch, Diane A. , Sun, Chen , Zhao, Xuefang , Zhou, Weichen , Frisbie, Trenton J., Cherskov, Adriana , Pochareddy, Sirisha , Kleinman, Joel E , Hyde, Thomas M , Straub, Richard E , Walsh, Christopher A , Urban, Alexander E , Leckman, James F , Weinberger, Daniel R , Vaccarino, Flora M , Abyzov, Alexej , Shin, Joo Heon , Zhou, Bo , Šuvakov, Milovan , Bae, Taejeong , Wang, Yifan , Jang, Yeongjun , Network§, Brain Somatic Mosaicism, Leckman, James F. , Park, Peter J. , Gage, Fred H , Gleeson, Joseph G. , Courchesne, Eric, Roy, Subhojit , Akbarian, Schahram , Coulter, Michael E. , Ganz, Javier , Hill, Robert, Huang, August Yue , Khoshkhoo, Sattar , Lee, Alice , Lodato, Michael A. , Maury, Eduardo A. , Rodin, Rachel E. , Zhou, Zinan , Chu, Chong , Cortés‐Ciriano, Isidro , Dou, Yanmei , Gulhan, D. , Viswanadham, Vinay , Jones, Attila , Langmead, Ben , Erwin, Jennifer A. , Jaffe, Andrew E. , Zhu, Xiaowei , Juan, David , Marquès‐Bonet, Tomàs , Breuss, Martin W. , Kidd, Jeffrey M. , Kopera, Huira C. , Kwan, Kenneth Y , Mills, Ryan E. , Moldovan, John B. , Scuderi, Soraya

Mayo Clinic

Science | July 28, 2022 | Volume: 377 | Issue: 6605 | Pages: 511-517

10.1126/science.abm6222 | PMID 35901164 Get It

We analyzed 131 human brains (44 neurotypical, 19 with Tourette syndrome, 9 with schizophrenia, and 59 with autism) for somatic mutations after whole genome sequencing to a depth of more than 200×. Typically, brains had 20 to 60 detectable single-nucleotide mutations, but ~6% of brains harbored hundreds of somatic mutations. Hypermutability was associated with age and damaging mutations in genes implicated in cancers and, in some brains, reflected in vivo clonal expansions. Somatic duplications, likely arising during development, were found in ~5% of normal and diseased brains, reflecting background mutagenesis. Brains with autism were associated with mutations creating putative transcription factor binding motifs in enhancer-like regions in the developing brain. The top-ranked affected motifs corresponded to MEIS (myeloid ectopic viral integration site) transcription factors, suggesting a potential link between their involvement in gene regulation and autism.
Infantile suprasellar tumor diagnosed as a pineoblastoma RB1 subgroup and treatment challenges: A pediatric SNO Molecular Tumor Board
Rubens, Jeffrey , Erker, Craig , Lindsay, Holly , Ho, Ben, Li, Bryan , Bouffet, Éric , Cohen, Alan R. , Ertl-Wagner, Birgit, Mahajan, Anita , Zacharoulis, Stergios, Packer, Roger J. , Rubens, Jeffrey A , Bouffet, Eric , Eberhart, Charles G. , Ertl-Wagner, Birgit, Huang, Annie

Mayo Clinic

Neuro-Oncology Advances | June 14, 2022 | Volume: 4 | Issue: 1 | Pages: No page available

10.1093/noajnl/vdac092 | PMID 35821675 Get It

Longitudinal Shifts of Solid Tumor and Liquid Biopsy Sequencing Concordance in Metastatic Breast Cancer
Liu, Minetta C. , MacKay, Matthew , Kase, Matthew, Piwowarczyk, Aneta, Lo, Christine , Schaeffer, Jeff, Finkle, Justin D. , Mason, Christopher E. , Beaubier, Nike , Blackwell, Kimberly , Park, Ben Ho , Schaeffer, Jeff, Mason, Christopher E

Mayo Clinic

JCO Precision Oncology | June 6, 2022 | Volume: No volume available | Issue: 6 | Pages: No page available

10.1200/po.21.00321 | PMID 35721584 Get It

PURPOSETissue-based next-generation sequencing (NGS) in metastatic breast cancer (mBC) is limited by the inability to noninvasively track tumor evolution. Cell-free DNA (cfDNA) NGS has made sequential testing feasible; however, the relationship between cfDNA and tissue-based testing in mBC is not well understood. Here, we evaluate concordance between tissue and cfDNA NGS relative to cfDNA sampling frequency in a large, clinically annotated mBC data set.METHODSTempus LENS was used to analyze deidentified records of mBC cases with Tempus xT (tissue) and xF (cfDNA) sequencing results. Then, various metrics of concordance were assessed within overlapping probe regions of the tissue and cfDNA assays (104 genes), focusing on pathogenic variants. Variant allele frequencies of discordant and concordant pathogenic variants were also compared. Analyses were stratified by mBC subtype and time between tests.RESULTSRecords from 300 paired tissue and liquid biopsies were analyzed. Median time between tissue and blood collection was 78.5 days (standard deviation = 642.99). The median number of pathogenic variants/patient was one for cfDNA and two for tissue. Across the cohort, 77.8% of pathogenic tissue variants were found in cfDNA and 75.7% of pathogenic cfDNA variants were found in tissue when tests were ≤ 7 days apart, which decreased to 50.3% and 51.8%, respectively, for > 365 days. Furthermore, the median patient-level variant concordance was 67% when tests were ≤7 days apart and 30%-37% when > 30 days. The median variant allele frequencies of discordant variants were generally lower than those of concordant variants within the same time frame.CONCLUSIONWe observed high concordances between tissue and cfDNA results that generally decreased with longer durations between tests. Thus, cfDNA NGS reliably measures tissue genomics and is likely beneficial for longitudinal monitoring of molecular changes in mBC.
MEK-inhibitor (inh) and hydroxychloroquine (HCQ) in KRAS-mutated advanced pancreatic ductal adenocarcinoma (PDAC).
Mehdi, Maahum , Thalji, Samih Z, Shreenivas, Aditya , Thomas, James P. , Christians, Kathleen K. , Evans, Douglas B. , Hall, William A. , Erickson, Beth , Yazdanpanah, Omid , Aldakkak, Mohammed , Holden, Mary Beth, George, Ben , Oxencis, Carolyn, Chakrabarti, Sakti , Thapa, Bicky , Ahmed, Gulrayz , Kurzrock, Razelle , Tsai, Susan , McFall, Thomas B. , Kamgar, Mandana

Mayo Clinic

Journal of Clinical Oncology | June 6, 2022 | Volume: 40 | Issue: 16_suppl | Pages: e16260-e16260

10.1200/jco.2022.40.16_suppl.e16260 Get It

e16260 Background: Therapeutic inhibition of constitutive signaling mediated by mutated KRAS in PDAC remains a challenge except for modest success reported with KRAS G12C inhibition. A combinatorial strategy utilizing simultaneous MEK and autophagy inhibition holds therapeutic promise based on mechanism of action and preclinical data. We described characteristics and outcomes of patients (pts) treated with MEK-inh and HCQ at our institution. Methods: Ten KRAS-mutated advanced PDAC pts were treated with trametinib-HCQ (n = 9) or cobimetinib-HCQ (n = 1) off label due to lack of standard treatment options or toxicity concerns with cytotoxic systemic therapy. Trametinib dose was 2 mg once daily orally, Cobimetinib dose was 20 mg BID orally for 3/4 weeks cycles. HCQ was started at 200 mg BID and up-titrated weekly to 600 mg BID. Description of baseline and treatment (tx) characteristics, safety and efficacy is provided. Results: Median age at diagnosis was 61.3 years, and 7 pts were female. The number of prior lines of tx were 0/1/2/3/4 in 3/2/1/2/2 pts, respectively. KRAS mutations were: G12R/G12D/G12V/Q61H in 6/2/1/1 pts. Median overall survival was 6.6 months (m) in all pts, and 6.6/1.7 m in KRAS G12R/other KRAS (p = 0.31). Median progression-free survival was 5.7/6.2/1.5 m in all/ KRAS G12R/other KRAS (p = 0.16). Among 8 pts with evaluable response, 1 (12%) had partial response ( KRAS G12R) and 4 (50%) stable disease (3/4 KRAS G12R) as best response with disease control rate of 63%/80%/33% in total/ KRAS G12R/other KRAS (p = 0.29). Toxicity data are summarized in table 1. Conclusions: MEK-inh-HCQ demonstrated modest efficacy and manageable toxicities among KRAS G12R PDAC pts. Unlike G12D and G12V mutations in the KRAS gene, G12R is defective of conductive interactions for both PI3Ka and NF1. This ultimately results in a weakened signal being shunted through MAPK cascade and provides a unique opportunity where MEK inh can ablate signaling without the alternate pathways and WT-RAS isoforms compensating. Furthermore, as activation of PI3Ka is known to suppress autophagy, its lack of activation by KRAS G12R further sensitizes cells to HCQ. The combination therapy MEK-inh-HCQ is therefore mechanistically-rationale and warrants the further investigation of KRAS G12R as an actionable biomarker.[Table: see text]